

# Coverage, Billing, and Financial Assistance

## For Foundation Medicine Patients

*Our experience  
shows that*

# 84%

**of patients  
have \$0 financial  
responsibility**

for Foundation  
Medicine Testing<sup>1</sup>

As part of our FoundationAccess™ program, for each comprehensive genomic profiling test ordered, we complete a benefits investigation and reach out to all patients whom we expect may have out-of-pocket costs.

# 86%

**of patients  
have a financial  
responsibility  
of \$100 or less**

for Foundation  
Medicine Testing<sup>2</sup>

As part of our FoundationAccess™ program, for each comprehensive genomic profiling test ordered, we complete a benefits investigation and reach out to all patients whom we expect may have out-of-pocket costs.

## Insurance Coverage Information

- All Foundation Medicine tests are covered by Original Medicare<sup>3</sup> and Medicare Advantage<sup>4</sup> for qualifying patients.<sup>5,6</sup>
- Qualifying patients with Original Medicare<sup>3</sup> have no out-of-pocket costs for Foundation Medicine comprehensive genomic profiling tests.
- Some commercial health plans such as Cigna and many BlueCross BlueShield plans offer coverage for Foundation Medicine testing services.<sup>7,8</sup>

## Billing Information

- Foundation Medicine will make every attempt to support insurance coverage and payment for testing. If your insurance company denies coverage for a Foundation Medicine test, with your consent, we will work to obtain coverage and pursue appeals.
- Foundation Medicine only bills patients after following the entire claims process. Your out-of-pocket cost will depend on your insurance plan and may include deductibles, co-insurances, copays, or non-covered charges.

## FOUNDATIONACCESS™

Foundation Medicine is committed to providing patients with resources and support throughout the testing process with the help of the FoundationAccess program. After your doctor orders a Foundation Medicine test and we receive your sample, we will contact you by phone, or mail you materials, to share important information about what you can expect as your test moves forward.

- Financial assistance is available for qualifying patients who have out-of-pocket costs associated with Foundation Medicine testing.\* Financial assistance is based on need and can be applied for at any time before during or after testing by filling out a financial assistance application at:  
**[www.foundationmedicine.com/aid](http://www.foundationmedicine.com/aid)**

\* Foundation Medicine's Financial Assistance Program is only available to patients whose tests were ordered within the United States and U.S. territories.



# Questions

The Foundation Medicine team is here to help. You may receive an Explanation of Benefits (EOB) – this is not a bill. If you have an EOB or bill in hand and have any questions, please contact our billing department.

**Call: 877.246.9204**

**Email: [foundationmedicine@mylabbill.com](mailto:foundationmedicine@mylabbill.com)**

**Fax: 440.528.6010**



## References

1. Data on File, Foundation Medicine, Inc., 2021. Based on settled claims from 1/1/20 to 3/31/21 for all tests offered by Foundation Medicine and reported during that time before considering any financial assistance. 58% of commercially insured and 95% of Medicare and Medicare Advantage patients paid \$0 for Foundation Medicine testing.
2. Data on File, Foundation Medicine, Inc., 2021. Based on settled claims from 1/1/20 to 3/31/21 for all tests offered by Foundation Medicine and reported during that time before considering any financial assistance. 63% of commercially insured and 98% of Medicare and Medicare Advantage patients had or qualified for a payment of \$100 or less for Foundation Medicine testing.
3. Medicare administered by federal government.
4. Medicare administered by private insurers.
5. For FoundationOne®CDx and FoundationOne®Liquid CDx, see “Decision for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced cancer – CAG-00450R.” (See Appendix B) available in the Medicare Coverage Database, <https://www.cms.gov/medicare-coverage-database/new-search/search.aspx>.
6. For FoundationOne®Heme, see the “Local Coverage Determination (LCD): MoIDX: NEXT-GENERATION Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies (L38047) available in the Medicare Coverage Database, <https://www.cms.gov/medicare-coverage-database/new-search/search.aspx>
7. A select number of commercial payers have developed medical policy coverage for Foundation Medicine’s FoundationOne CDx and FoundationOne Liquid CDx tests for commercially-insured patients. Foundation Medicine’s other CGP test (FoundationOne Heme) has limited third party payer commercial coverage. In each case, coverage is pursuant to applicable payer medical policy and patient benefit plans.
8. Medicare and Medicare Advantage members have coverage of FoundationOne CDx, FoundationOne Liquid CDx and FoundationOne Heme in accordance with the Centers for Medicare and Medicaid Services (CMS) national coverage determination (NCD) criteria.

FoundationOne®CDx and FoundationOne®Liquid CDx are qualitative next-generation sequencing based *in vitro* diagnostic tests for advanced cancer patients with solid tumors and are for prescription use only. FoundationOne CDx utilizes FFPE tissue and analyzes 324 genes as well as genomic signatures. FoundationOne Liquid CDx analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes. The tests are companion diagnostics to identify patients who may benefit from treatment with specific therapies in accordance with the therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the tests does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy for testing with FoundationOne CDx when archival tissue is not available which may pose a risk. Patients who are tested with FoundationOne Liquid CDx and are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if available. For the complete label, including companion diagnostic indications and important risk information, please visit [www.FICDXLabel.com](http://www.FICDXLabel.com) and [www.FILCDXLabel.com](http://www.FILCDXLabel.com).

FoundationOne Heme was developed and its performance characteristics determined by Foundation Medicine. It has not been cleared or approved by the U.S. Food and Drug Administration. For more information on this laboratory developed test please see the Technical Specifications at [www.foundationmedicine.com/heme](http://www.foundationmedicine.com/heme).